Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans
Open Access
- 31 January 2024
- journal article
- review article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (2) , 251-269
Abstract
In the recent decade, scientific communities have toiled to tackle the emerging burden of drug-resistant tuberculosis (DR-TB) and rapidly growing opportunistic nontuberculous mycobacteria (NTM). Among these, two neglected mycobacteria species of the Acinetobacter family, Mycobacterium leprae and Mycobacterium ulcerans, are the etiological agents of leprosy and Buruli ulcer infections, respectively, and fall under the broad umbrella of neglected tropical diseases (NTDs). Unfortunately, lackluster drug discovery efforts have been made against these pathogenic bacteria in the recent decade, resulting in the discovery of only a few countable hits and majorly repurposing anti-TB drug candidates such as telacebec (Q203), P218, and TB47 for current therapeutic interventions. Major ignorance in drug candidate identification might aggravate the dramatic consequences of rapidly spreading mycobacterial NTDs in the coming days. Therefore, this Review focuses on an up-to-date account of drug discovery efforts targeting selected druggable targets from both bacilli, including the accompanying challenges that have been identified and are responsible for the slow drug discovery. Furthermore, a succinct discussion of the all-new possibilities that could be alternative solutions to mitigate the neglected mycobacterial NTD burden and subsequently accelerate the drug discovery effort is also included. We anticipate that the state-of-the-art strategies discussed here may attract major attention from the scientific community to navigate and expand the roadmap for the discovery of next-generation therapeutics against these NTDs.Keywords
Funding Information
- National Research Foundation
- South African Medical Research Council
This publication has 158 references indexed in Scilit:
- Discovery of Selective Menaquinone Biosynthesis Inhibitors against Mycobacterium tuberculosisJournal of Medicinal Chemistry, 2012
- Structure of the cystathionine γ-synthase MetB fromMycobacterium ulceransActa Crystallographica Section F Structural Biology and Crystallization Communications, 2011
- Design, Synthesis, and Study of a Mycobactin−Artemisinin Conjugate That Has Selective and Potent Activity against Tuberculosis and MalariaJournal of the American Chemical Society, 2011
- Rapid Assessment of Antibacterial Activity against Mycobacterium ulcerans by Using Recombinant Luminescent StrainsAntimicrobial Agents and Chemotherapy, 2010
- Buruli ulcerClinics in Dermatology, 2009
- Phosphate coordination and movement of DNA in the Tn5 synaptic complex: role of the (R)YREK motifNucleic Acids Research, 2008
- The crystal structure of M. leprae ML2640c defines a large family of putative S‐adenosylmethionine‐dependent methyltransferases in mycobacteriaProtein Science, 2007
- Reconstructing the ancestor of Mycobacterium leprae: The dynamics of gene loss and genome reductionGenome Research, 2007
- Mechanism of thioamide drug action against tuberculosis and leprosyJournal of Experimental Medicine, 2007
- Massive gene decay in the leprosy bacillusNature, 2001